Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions
Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of the drugs that have not been approved by the FDA
.jpg?width=1200&auto=webp&trim=118,0,119,0#)
Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of the drugs that have not been approved by the FDA
